EGFR and head and neck squamous cell carcinoma: However, more than 10 years after Food and Drug Administration (FDA)-approval of the use of Cetuximab, an anti-EGFR monoclonal antibody, alone or in combination with either radiotherapy or chemotherapy, HNSCC patient outcome was only moderately improved [6].